Quantitative magnetic fractionation and a published mathematical model were used to characterize between-treatment differences in gametocyte density and prevalence in 70 Papua New Guinean children with uncomplicated Plasmodium falciparum and/or
Plasmodium vivax malaria randomized to one of two
artemisinin combination
therapies (
artemether-lumefantrine or
artemisinin-
naphthoquine) in an intervention trial. There was an initial rise in peripheral P. falciparum gametocyte density with both treatments, but it was more pronounced in the
artemisinin-
naphthoquine group. Model-derived estimates of the median pretreatment sequestered gametocyte population were 21/μl for
artemether-lumefantrine and 61/μl for
artemisinin-
naphthoquine (P < 0.001). The median time for P. falciparum gametocyte density to fall to <2.5/μl (below which transmission becomes unlikely) was 16 days in the
artemether-lumefantrine group and 20 days in
artemisinin-
naphthoquine group (P < 0.001). Gametocyte prevalence modeling suggested that
artemisinin-
naphthoquine-treated children became gametocytemic faster (median, 2.2 days) than
artemether-lumefantrine-treated children (median, 5.3 days; P < 0.001) and had a longer median P. falciparum gametocyte carriage time per individual (20 versus 13 days; P < 0.001). Clearance of P. vivax gametocytes was rapid (within 3 days) in both groups; however, consistent with the reappearance of asexual forms in the main trial, nearly 40% of children in the
artemether-lumefantrine group developed P. vivax gametocytemia between days 28 and 42 compared with 3% of children in the
artemisinin-
naphthoquine group. These data suggest that
artemisinin is less active than
artemether against sequestered gametocytes. Greater initial gametocyte release after
artemisinin-
naphthoquine increases the period of potential P. falciparum transmission by 4 days relative to
artemether-lumefantrine, but the longer elimination half-life of
naphthoquine than of
lumefantrine suppresses P. vivax recurrence and consequent gametocytemia.